Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy
Open Access
- 1 December 2015
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 59 (12), 7743-7752
- https://doi.org/10.1128/aac.00831-15
Abstract
The objective of this study was to investigate the risk of attenuated efficacy due to adaptive resistance for the siderophore-conjugated monocarbam SMC-3176 in Pseudomonas aeruginosa by using a pharmacokinetic/pharmacodynamic (PK/PD) approach. MICs were determined in cation-adjusted Mueller-Hinton broth (MHB) and in Chelex-treated, dialyzed MHB (CDMHB). Spontaneous resistance was assessed at 2× to 16× the MIC and the resulting mutants sequenced. Efficacy was evaluated in a neutropenic mouse thigh model at 3.13 to 400 mg/kg of body weight every 3 h for 24 h and analyzed for association with free time above the MIC ( fT >MIC). To closer emulate the conditions of the in vivo model, we developed a novel assay testing activity mouse whole blood (WB). All mutations were found in genes related to iron uptake: piuA , piuC , pirR , fecI , and pvdS . Against four P. aeruginosa isolates, SMC-3176 displayed predictable efficacy corresponding to the fT >MIC using the MIC in CDMHB ( R 2 = 0.968 to 0.985), with stasis to 2-log kill achieved at 59.4 to 81.1%. Efficacy did not translate for P. aeruginosa isolate JJ 4-36, as the in vivo responses were inconsistent with fT >MIC exposures and implied a threshold concentration that was greater than the MIC. The results of the mouse WB assay indicated that efficacy was not predictable using the MIC for JJ 4-36 and four additional isolates, against which in vivo failures of another siderophore-conjugated β-lactam were previously reported. SMC-3176 carries a risk of attenuated efficacy in P. aeruginosa due to rapid adaptive resistance preventing entry via the siderophore-mediated iron uptake systems. Substantial in vivo testing is warranted for compounds using the siderophore approach to thoroughly screen for this in vitro-in vivo disconnect in P. aeruginosa .Keywords
This publication has 30 references indexed in Scilit:
- Siderophore-dependent iron uptake systems as gates for antibiotic Trojan horse strategies against Pseudomonas aeruginosaMetallomics, 2014
- Adaptation-Based Resistance to Siderophore-Conjugated Antibacterial Agents by Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2013
- Pyridone-Conjugated Monobactam Antibiotics with Gram-Negative ActivityJournal of Medicinal Chemistry, 2013
- Biscatecholate–Monohydroxamate Mixed Ligand Siderophore–Carbacephalosporin Conjugates are Selective Sideromycin Antibiotics that Target Acinetobacter baumanniiJournal of Medicinal Chemistry, 2013
- Preparation, Gram-Negative Antibacterial Activity, and Hydrolytic Stability of Novel Siderophore-Conjugated Monocarbam DiolsACS Medicinal Chemistry Letters, 2011
- In Vitro Properties of BAL30072, a Novel Siderophore Sulfactam with Activity against Multiresistant Gram-Negative BacilliAntimicrobial Agents and Chemotherapy, 2010
- Iron uptake regulation in Pseudomonas aeruginosaBioMetals, 2009
- Siderophore-Based Iron Acquisition and Pathogen ControlMicrobiology and Molecular Biology Reviews, 2007
- State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and MenClinical Infectious Diseases, 1998
- Mapping of mutations affecting pyoverdine production inPseudomonas aeruginosaFEMS Microbiology Letters, 1986